⟵ Back to Search Results

BGB-A317-203

Completed

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Beigene Study ID info

BGB-A317-203

ClinicalTrials.gov ID info

NCT03209973

China Drug Trials ID info

CTR20170119

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan